Total operating income was up by 35.7 per cent to Rs 3162.1 crores in Q4 FY2014-15
Aurobindo Pharma has posted its Q4/FY2014-15 results. In Q4 FY2014-15, the total operating income was up by 35.7 per cent to Rs 3162.1 crores (Rs 2329.8 crores). The operating profit (EBIDTA) before Fx was at 20.7 per cent (32 per cent). The pperating profit (EBIDTA) before Fx was Rs 656.1 crores (Rs 744.6 crores). Profit before tax (PBT) before Fx was at Rs 555.6 crores (Rs 631.4 crores). Profit after tax (PAT) was at Rs 403.8 crores (Rs 501.8 crores). The basic and diluted EPS was Rs 13.84 (Rs 17.23 ) and Rs 13.84 (Rs 17.21) respectively.
In FY2014-15, the total operating income was up by 49.6 per cent to Rs 12120.5 crores (Rs 8099.8 crores). The operating profit (EBIDTA) before Fx was at 21.2 per cent (26.4 per cent). The operating profit (EBIDTA) before Fx was up 20.1 per cent to Rs 2563.6 crores (Rs 2134.5 crores). PBT before Fx was up by 28.3 per cent to Rs 2227.5 crores (Rs 1735.6 crores). PAT was up by 34.4 per cent to Rs 1575.8 crores (Rs 1172.9 crores). The basic and diluted EPS was Rs 54.05 (Rs 40.27) and Rs 54 (Rs 40.22) respectively. The formulation sales was up by 77.7 per cent to Rs 9558.6 crores (Rs 5378.5 crores). API sales were down by 5.5 per cent to Rs 2706.2 crores (Rs 2864 crores). Formulations sales constitute 77.9 per cent (65.3 per cent) and API 22.1 per cent (34.7 per cent) of gross sales.
The board has inter-alia considered and approved third interim dividend at 100 per cent (Rs 1 per equity share of the face value of Rs 1 each) in addition to the interim dividends of 350 per cent (Rs 3.5 per equity share of the face value of Rs 1 each), aggregating to 450 per cent (Rs 4.50 per equity share of the face value of Rs 1 each) for the year 2014-15. The board did not recommend any further dividend for the year 2014-15. The board has recommended for issue of one bonus equity share for every one equity share held as on a record date to be determined.
N Govindarajan, Managing Director, Aurobindo Pharma, “We are pleased to report another year of strong performance with sustained margins. We believe that the acquired businesses would further enhance the performance going forward.”
Comments are closed.